{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:25"], "contactPoint": {"@type": "vcard:Contact", "fn": "NIH", "hasEmail": "mailto:info@nih.gov"}, "description": "The evidence base for drug treatment of hypertension is strong. Early trials \nusing thiazide diuretics suggested a shortfall in prevention of coronary heart \ndisease. The superiority of newer drugs has been widely advocated but trial \nevidence does not support an advantage of beta-blockers, angiotensin converting \nenzyme inhibitors, calcium channel blockers or alpha-blockers for this outcome. \nEven meta-analyses have failed to clarify matters. If this issue is to be \nsettled, bigger and better trials of longer duration in high-risk patients are \nneeded. Meanwhile, the importance of rigorous blood pressure control using \nmultiple drugs has been established. This should be the focus of our attention \nrather than agonising over differences in cause-specific outcomes that may not \nbe generalisable to all patient populations.", "distribution": [{"@type": "dcat:Distribution", "description": "Visit the original government dataset for complete information, documentation, and data access.", "downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59626/", "mediaType": "text/html", "title": "Official Government Data Source"}], "identifier": "https://healthdata.gov/api/views/qkzb-5kr7", "issued": "2025-07-14", "keyword": ["nih", "blood-pressure-control", "antihypertensive-drugs", "cardiovascular-outcomes", "hypertension-treatment"], "landingPage": "https://healthdata.gov/d/qkzb-5kr7", "modified": "2025-09-06", "programCode": ["009:032"], "publisher": {"@type": "org:Organization", "name": "National Institutes of Health"}, "theme": ["NIH"], "title": "Debate: does it matter how you lower blood pressure?"}